Clusterin in Alzheimer's disease

Advances in Clinical Chemistry

Volumn 56, Issue , 2012, Pages 155-173

  Wu, Zhong Chen ^a   Yu, Jin Tai ^a   Li, Yang ^a   Tan, Lan ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid ; Blood brain barrier; Clusterin; Megalin

Indexed keywords

EID: 84855320950     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394317-0.00011-X     Document Type: Chapter

References (148)

1. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5(6):831-839.
2. Tycko B., Feng L., Nguyen L., Francis A., Hays A., Chung W.Y., et al. Polymorphisms in the human apolipoprotein-J/clusterin gene: ethnic variation and distribution in Alzheimer's disease. Hum. Genet. 1996, 98(4):430-436.
3. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1094-1099.
4. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1088-1093.
5. Yu J.T., Li L., Zhu Q.X., Zhang Q., Zhang W., Wu Z.C., et al. Implication of CLU gene polymorphisms in Chinese patients with Alzheimer's disease. Clin. Chim. Acta 2010, 411(19-20):1516-1519.
6. Kirszbaum L., Bozas S.E., Walker I.D. SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett. 1992, 297(1-2):70-76.
7. Murphy B.F., Kirszbaum L., Walker I.D., d'Apice A.J. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J. Clin. Invest. 1988, 81(6):1858-1864.
8. Wong P., Taillefer D., Lakins J., Pineault J., Chader G., Tenniswood M. Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur. J. Biochem. 1994, 221(3):917-925.
9. Stewart E.M., Aquilina J.A., Easterbrook-Smith S.B., Murphy-Durland D., Jacobsen C., Moestrup S., et al. Effects of glycosylation on the structure and function of the extracellular chaperone clusterin. Biochemistry 2007, 46(5):1412-1422.
10. Jenne D.E., Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc. Natl. Acad. Sci. USA 1989, 86(18):7123-7127.
11. Jenne D.E., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 1992, 17(4):154-159.
12. Kirszbaum L., Sharpe J.A., Murphy B., d'Apice A.J., Classon B., Hudson P., et al. Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO J. 1989, 8(3):711-718.
13. Tsuruta J.K., Wong K., Fritz I.B., Griswold M.D. Structural analysis of sulphated glycoprotein 2 from amino acid sequence. Relationship to clusterin and serum protein 40,40. Biochem. J. 1990, 268(3):571-578.
14. Kimura K., Asami K., Yamamoto M. Effect of heat shock treatment on the production of variant testosterone-repressed prostate message-2 (TRPM-2) mRNA in culture cells. Cell Biochem. Funct. 1997, 15(4):251-257.
15. Leskov K.S., Klokov D.Y., Li J., Kinsella T.J., Boothman D.A. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 2003, 278(13):11590-11600.
16. Wong P., Pfeffer B.A., Bernstein S.L., Chambers M.L., Chader G.J., Zakeri Z.F., et al. Clusterin protein diversity in the primate eye. Mol. Vis. 2000, 6:184-191.
17. Reddy K.B., Jin G., Karode M.C., Harmony J.A., Howe P.H. Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 1996, 35(19):6157-6163.
18. Aronow B.J., Lund S.D., Brown T.L., Harmony J.A., Witte D.P. Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proc. Natl. Acad. Sci. USA 1993, 90(2):725-729.
19. French L.E., Chonn A., Ducrest D., Baumann B., Belin D., Wohlwend A., et al. Murine clusterin: molecular cloning and mRNA localization of a gene associated with epithelial differentiation processes during embryogenesis. J. Cell Biol. 1993, 122(5):1119-1130.
20. Harr S.D., Uint L., Hollister R., Hyman B.T., Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J. Neurochem. 1996, 66(6):2429-2435.
21. de Silva H.V., Harmony J.A., Stuart W.D., Gil C.M., Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990, 29(22):5380-5389.
22. Duguid J.R., Bohmont C.W., Liu N.G., Tourtellotte W.W. Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc. Natl. Acad. Sci. USA 1989, 86(18):7260-7264.
23. Danik M., Chabot J.G., Hassan-Gonzalez D., Suh M., Quirion R. Localization of sulfated glycoprotein-2/clusterin mRNA in the rat brain by in situ hybridization. J. Comp. Neurol. 1993, 334(2):209-227.
24. Pasinetti G.M., Johnson S.A., Oda T., Rozovsky I., Finch C.E. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J. Comp. Neurol. 1994, 339(3):387-400.
25. Zwain I.H., Grima J., Stahler M.S., Saso L., Cailleau J., Verhoeven G., et al. Regulation of Sertoli cell alpha 2-macroglobulin and clusterin (SGP-2) secretion by peritubular myoid cells. Biol. Reprod. 1993, 48(1):180-187.
26. Saura J., Petegnief V., Wu X., Liang Y., Paul S.M. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J. Neurochem. 2003, 85(6):1455-1467.
27. Charnay Y., Imhof A., Vallet P.G., Hakkoum D., Lathuiliere A., Poku N., et al. Clusterin expression during fetal and postnatal CNS development in mouse. Neuroscience 2008, 155(3):714-724.
28. Petropoulou C., Trougakos I.P., Kolettas E., Toussaint O., Gonos E.S. Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett. 2001, 509(2):287-297.
29. Trougakos I.P., Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 2002, 34(11):1430-1448.
30. Choi-Miura N.H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., et al. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol. 1992, 83(3):260-264.
31. McGeer P.L., Kawamata T., Walker D.G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992, 579(2):337-341.
32. Polihronis M., Paizis K., Carter G., Sedal L., Murphy B. Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. J. Neurol. Sci. 1993, 115(2):230-233.
33. Schreiber S.S., Tocco G., Najm I., Baudry M. Seizure activity causes a rapid increase in sulfated glycoprotein-2 messenger RNA in the adult but not the neonatal rat brain. Neurosci. Lett. 1993, 153(1):17-20.
34. Nilselid A.M., Davidsson P., Nagga K., Andreasen N., Fredman P., Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem. Int. 2006, 48(8):718-728.
35. Sihlbom C., Davidsson P., Sjogren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem. Res. 2008, 33(7):1332-1340.
36. Herault Y., Chatelain G., Brun G., Michel D. V-src-induced-transcription of the avian clusterin gene. Nucleic Acids Res. 1992, 20(23):6377-6383. PMCID: 334530.
37. Michel D., Chatelain G., Herault Y., Brun G. The expression of the avian clusterin gene can be driven by two alternative promoters with distinct regulatory elements. Eur. J. Biochem. 1995, 229(1):215-223.
38. Michel D., Chatelain G., North S., Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. 1997, 328(Pt. 1):45-50.
39. Rosemblit N., Chen C.L. Regulators for the rat clusterin gene: DNA methylation and cis-acting regulatory elements. J. Mol. Endocrinol. 1994, 13(1):69-76.
40. Wong P., Pineault J., Lakins J., Taillefer D., Leger J., Wang C., et al. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J. Biol. Chem. 1993, 268(7):5021-5031.
41. Loison F., Debure L., Nizard P., le Goff P., Michel D., le Drean Y. Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem. J. 2006, 395(1):223-231.
42. Jin G., Howe P.H. Regulation of clusterin gene expression by transforming growth factor beta. J. Biol. Chem. 1997, 272(42):26620-26626.
43. Gutacker C., Klock G., Diel P., Koch-Brandt C. Nerve growth factor and epidermal growth factor stimulate clusterin gene expression in PC12 cells. Biochem. J. 1999, 339(Pt. 3):759-766. PMCID: 1220214.
44. Jin G., Howe P.H. Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. Eur. J. Biochem. 1999, 263(2):534-542.
45. Criswell T., Beman M., Araki S., Leskov K., Cataldo E., Mayo L.D., et al. Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J. Biol. Chem. 2005, 280(14):14212-14221.
46. Zwain I.H., Grima J., Cheng C.Y. Regulation of clusterin secretion and mRNA expression in astrocytes by cytokines. Mol. Cell. Neurosci. 1994, 5(3):229-237.
47. Nuutinen T., Suuronen T., Kyrylenko S., Huuskonen J., Salminen A. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem. Int. 2005, 47(8):528-538.
48. Suuronen T., Nuutinen T., Ryhanen T., Kaarniranta K., Salminen A. Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochem. Biophys. Res. Commun. 2007, 357(2):397-401.
49. Rauhala H.E., Porkka K.P., Saramaki O.R., Tammela T.L., Visakorpi T. Clusterin is epigenetically regulated in prostate cancer. Int. J. Cancer 2008, 123(7):1601-1609.
50. Grassilli E., Bettuzzi S., Troiano L., Ingletti M.C., Monti D., Corti A., et al. SGP-2, apoptosis, and aging. Ann. N. Y. Acad. Sci. 1992, 663:471-474.
51. Trougakos I.P., Poulakou M., Stathatos M., Chalikia A., Melidonis A., Gonos E.S. Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp. Gerontol. 2002, 37(10-11):1175-1187.
52. Ishikawa T., Zhu B.L., Li D.R., Zhao D., Michiue T., Maeda H. Age-dependent increase of clusterin in the human pituitary gland. Leg. Med. (Tokyo) 2006, 8(1):28-33.
53. Patel N.V., Wei M., Wong A., Finch C.E., Morgan T.E. Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neurosci. Lett. 2004, 371(2-3):199-204.
54. Ekici A.I., Eren B., Turkmen N., Comunoglu N., Fedakar R. Clusterin expression in non-neoplastic adenohypophyses and pituitary adenomas: cytoplasmic clusterin localization in adenohypophysis is related to aging. Endocr. Pathol. 2008, 19(1):47-53.
55. Morgan T.E., Xie Z., Goldsmith S., Yoshida T., Lanzrein A.S., Stone D., et al. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 1999, 89(3):687-699.
56. Boggs L.N., Fuson K.S., Baez M., Churgay L., McClure D., Becker G., et al. Clusterin (Apo J) protects against in vitro amyloid-beta (1-40) neurotoxicity. J. Neurochem. 1996, 67(3):1324-1327.
57. Wilson M.R., Easterbrook-Smith S.B. Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG. Biochim. Biophys. Acta 1992, 1159(3):319-326.
58. Blaschuk O., Burdzy K., Fritz I.B. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. 1983, 258(12):7714-7720.
59. Wilson M.R., Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 2000, 25(3):95-98.
60. Park D.C., Yeo S.G., Wilson M.R., Yerbury J.J., Kwong J., Welch W.R., et al. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 2008, 10(9):964-972.
61. Trougakos I.P., Pawelec G., Tzavelas C., Ntouroupi T., Gonos E.S. Clusterin/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells. Biogerontology 2006, 7(5-6):375-382.
62. Strocchi P., Smith M.A., Perry G., Tamagno E., Danni O., Pession A., et al. Clusterin up-regulation following sub-lethal oxidative stress and lipid peroxidation in human neuroblastoma cells. Neurobiol. Aging 2006, 27(11):1588-1594.
63. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 1995, 27(7):633-645.
64. DeMattos R.B., O'Dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2002, 99(16):10843-10848.
65. Rosenberg M.E., Girton R., Finkel D., Chmielewski D., Barrie A., Witte D.P., et al. Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol. Cell. Biol. 2002, 22(6):1893-1902.
66. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004, 41(2):193-202.
67. Marinelli M., Quaglino D., Bettuzzi S., Strocchi P., Davalli P., Corti A. Increased levels of clusterin mRNA in the ventral prostate of the aging rat are associated to increases in cuboidal (atrophic) cell population and not to changes in apoptotic activity. Biochem. Cell Biol. 1994, 72(11-12):515-521.
68. French L.E., Wohlwend A., Sappino A.P., Tschopp J., Schifferli J.A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 1994, 93(2):877-884.
69. Michel D., Moyse E., Trembleau A., Jourdan F., Brun G. Clusterin/ApoJ expression is associated with neuronal apoptosis in the olfactory mucosa of the adult mouse. J. Cell Sci. 1997, 110(Pt. 14):1635-1645.
70. Ho S.M., Leav I., Ghatak S., Merk F., Jagannathan V.S., Mallery K. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat. Am. J. Pathol. 1998, 153(1):131-139.
71. Han B.H., DeMattos R.B., Dugan L.L., Kim-Han J.S., Brendza R.P., Fryer J.D., et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat. Med. 2001, 7(3):338-343.
72. Wicher G.K., Aldskogius H. Adult motor neurons show increased susceptibility to axotomy-induced death in mice lacking clusterin. Eur. J. Neurosci. 2005, 21(7):2024-2028.
73. McLaughlin L., Zhu G., Mistry M., Ley-Ebert C., Stuart W.D., Florio C.J., et al. Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J. Clin. Invest. 2000, 106(9):1105-1113.
74. Bailey R.W., Aronow B., Harmony J.A., Griswold M.D. Heat shock-initiated apoptosis is accelerated and removal of damaged cells is delayed in the testis of clusterin/ApoJ knock-out mice. Biol. Reprod. 2002, 66(4):1042-1053.
75. Wehrli P., Charnay Y., Vallet P., Zhu G., Harmony J., Aronow B., et al. Inhibition of post-ischemic brain injury by clusterin overexpression. Nat. Med. 2001, 7(9):977-979.
76. Caccamo A.E., Scaltriti M., Caporali A., D'Arca D., Scorcioni F., Candiano G., et al. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Ann. N. Y. Acad. Sci. 2003, 1010:514-519.
77. Caccamo A.E., Scaltriti M., Caporali A., D'Arca D., Scorcioni F., Astancolle S., et al. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochem. J. 2004, 382(Pt. 1):157-168.
78. Caccamo A.E., Scaltriti M., Caporali A., D'Arca D., Corti A., Corvetta D., et al. Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ. 2005, 12(1):101-104.
79. Bettuzzi S., Rizzi F. Chapter 5: nuclear CLU (nCLU) and the fate of the cell. Adv. Cancer Res. 2009, 104:59-88.
80. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81(2):741-766.
81. McGeer P.L., Klegeris A., Walker D.G., Yasuhara O., McGeer E.G. Pathological proteins in senile plaques. Tohoku J. Exp. Med. 1994, 174(3):269-277.
82. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002, 416(6880):507-511.
83. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416(6880):535-539.
84. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 2000, 50(4):305-315.
85. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.H., Tomita M., Wisniewski T., et al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 1993, 293(Pt. 1):27-30.
86. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E., et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 1995, 136(1):22-31.
87. Hochgrebe T., Pankhurst G.J., Wilce J., Easterbrook-Smith S.B. pH-dependent changes in the in vitro ligand-binding properties and structure of human clusterin. Biochemistry 2000, 39(6):1411-1419.
88. Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., Dobson C.M., et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007, 21(10):2312-2322.
89. Wilson M.R., Yerbury J.J., Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol. Biosyst. 2008, 4(1):42-52.
90. Paresce D.M., Ghosh R.N., Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996, 17(3):553-565.
91. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 2003, 9(4):453-457.
92. Hammad S.M., Ranganathan S., Loukinova E., Twal W.O., Argraves W.S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J. Biol. Chem. 1997, 272(30):18644-18649.
93. Cole G.M., Ard M.D. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microsc. Res. Tech. 2000, 50(4):316-324.
94. Bartl M.M., Luckenbach T., Bergner O., Ullrich O., Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 2001, 271(1):130-141.
95. Lucarelli M., Gennarelli M., Cardelli P., Novelli G., Scarpa S., Dallapiccola B., et al. Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. FEBS Lett. 1997, 401(1):53-58.
96. Christie R.H., Freeman M., Hyman B.T. Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am. J. Pathol. 1996, 148(2):399-403.
97. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 2007, 27(5):909-918.
98. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 2004, 89(4):807-811.
99. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106(12):1489-1499.
100. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008, 118(12):4002-4013.
101. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 2000, 106(9):1159-1166.
102. Hussain M.M., Strickland D.K., Bakillah A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999, 19:141-172.
103. LaDu M.J., Shah J.A., Reardon C.A., Getz G.S., Bu G., Hu J., et al. Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J. Biol. Chem. 2000, 275(43):33974-33980.
104. Zlokovic B.V., Martel C.L., Matsubara E., McComb J.G., Zheng G., McCluskey R.T., et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. USA 1996, 93(9):4229-4234.
105. Chun J.T., Wang L., Pasinetti G.M., Finch C.E., Zlokovic B.V. Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp. Neurol. 1999, 157(1):194-201.
106. Shayo M., McLay R.N., Kastin A.J., Banks W.A. The putative blood-brain barrier transporter for the beta-amyloid binding protein apolipoprotein j is saturated at physiological concentrations. Life Sci. 1997, 60(7):PL115-PL118.
107. Calero M., Rostagno A., Frangione B., Ghiso J. Clusterin and Alzheimer's disease. Subcell. Biochem. 2005, 38:273-298.
108. Nuutinen T., Huuskonen J., Suuronen T., Ojala J., Miettinen R., Salminen A. Amyloid-beta 1-42 induced endocytosis and clusterin/apoJ protein accumulation in cultured human astrocytes. Neurochem. Int. 2007, 50(3):540-547.
109. Yerbury J.J., Wilson M.R. Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones 2010, 15(1):115-121.
110. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 1998, 8(1):65-72.
111. Li R., Yang L., Lindholm K., Konishi Y., Yue X., Hampel H., et al. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J. Neurosci. 2004, 24(7):1760-1771.
112. Grilli M., Goffi F., Memo M., Spano P. Interleukin-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J. Biol. Chem. 1996, 271(25):15002-15007.
113. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95(11):6448-6453.
114. Bourne K.Z., Ferrari D.C., Lange-Dohna C., Rossner S., Wood T.G., Perez-Polo J.R. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J. Neurosci. Res. 2007, 85(6):1194-1204.
115. Kaltschmidt B., Uherek M., Volk B., Baeuerle P.A., Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 1997, 94(6):2642-2647.
116. Lukiw W.J., Bazan N.G. Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J. Neurosci. Res. 1998, 53(5):583-592.
117. Boissiere F., Hunot S., Faucheux B., Duyckaerts C., Hauw J.J., Agid Y., et al. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 1997, 8(13):2849-2852.
118. Terai K., Matsuo A., McGeer P.L. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res. 1996, 735(1):159-168.
119. Santilli G., Aronow B.J., Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J. Biol. Chem. 2003, 278(40):38214-38219.
120. Devauchelle V., Essabbani A., De Pinieux G., Germain S., Tourneur L., Mistou S., et al. Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. J. Immunol. 2006, 177(9):6471-6479.
121. Savkovic V., Gantzer H., Reiser U., Selig L., Gaiser S., Sack U., et al. Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem. Biophys. Res. Commun. 2007, 356(2):431-437.
122. Essabbani A., Margottin-Goguet F., Chiocchia G. Identification of clusterin domain involved in NF-kappaB pathway regulation. J. Biol. Chem. 2010, 285(7):4273-4277.
123. Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V., et al. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1998, 1(4):565-574.
124. Wong E., Cuervo A.M. Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 2010, 13(7):805-811.
125. Li Y., Grupe A., Rowland C., Nowotny P., Kauwe J.S., Smemo S., et al. DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum. Mol. Genet. 2006, 15(17):2560-2568.
126. Wu Z.C., Zhang W., Yu J.T., Zhang Q., Tian Y., Lu R.C., et al. Association of DAPK1 genetic variations with Alzheimer's disease in Han Chinese. Brain Res. 2011, 1374:129-133.
127. Zhu X., Raina A.K., Perry G., Smith M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004, 3(4):219-226.
128. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., et al. Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs 2007, 16(12):1921-1931.
129. Dyrks T., Dyrks E., Masters C.L., Beyreuther K. Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 1993, 324(2):231-236.
130. Bellomo G., Mirabelli F. Oxidative stress and cytoskeletal alterations. Ann. N. Y. Acad. Sci. 1992, 663:97-109.
131. Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., Wang C.Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 2005, 7(9):909-915.
132. Nie C., Tian C., Zhao L., Petit P.X., Mehrpour M., Chen Q. Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. J. Biol. Chem. 2008, 283(22):15359-15369.
133. Trougakos I.P., Lourda M., Antonelou M.H., Kletsas D., Gorgoulis V.G., Papassideri I.S., et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin. Cancer Res. 2009, 15(1):48-59.
134. Smale G., Nichols N.R., Brady D.R., Finch C.E., Horton W.E. Evidence for apoptotic cell death in Alzheimer's disease. Exp. Neurol. 1995, 133(2):225-230.
135. Anderson A.J., Su J.H., Cotman C.W. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 1996, 16(5):1710-1719.
136. Adamec E., Vonsattel J.P., Nixon R.A. DNA strand breaks in Alzheimer's disease. Brain Res. 1999, 849(1-2):67-77.
137. Martin L.J., Al-Abdulla N.A., Brambrink A.M., Kirsch J.R., Sieber F.E., Portera-Cailliau C. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res. Bull. 1998, 46(4):281-309.
138. Martin L.J. Neuronal cell death in nervous system development, disease, and injury (Review). Int. J. Mol. Med. 2001, 7(5):455-478.
139. Shannan B., Seifert M., Boothman D.A., Tilgen W., Reichrath J. Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle control. J. Mol. Histol. 2006, 37(5-7):183-188.
140. Kang S.W., Shin Y.J., Shim Y.J., Jeong S.Y., Park I.S., Min B.H. Clusterin interacts with SCLIP (SCG10-like protein) and promotes neurite outgrowth of PC12 cells. Exp. Cell Res. 2005, 309(2):305-315.
141. Wicher G., Fex-Svenningsen A., Velsecchi I., Charnay Y., Aldskogius H. Extracellular clusterin promotes neuronal network complexity in vitro. Neuroreport 2008, 19(15):1487-1491.
142. Morrow J.A., Hatters D.M., Lu B., Hochtl P., Oberg K.A., Rupp B., et al. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J. Biol. Chem. 2002, 277(52):50380-50385.
143. Dunker A.K., Oldfield C.J., Meng J., Romero P., Yang J.Y., Chen J.W., et al. The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics 2008, 9(Suppl. 2):S1.
144. Laping N.J., Morgan T.E., Nichols N.R., Rozovsky I., Young-Chan C.S., Zarow C., et al. Transforming growth factor-beta 1 induces neuronal and astrocyte genes: tubulin alpha 1, glial fibrillary acidic protein and clusterin. Neuroscience 1994, 58(3):563-572.
145. Morgan T.E., Laping N.J., Rozovsky I., Oda T., Hogan T.H., Finch C.E., et al. Clusterin expression by astrocytes is influenced by transforming growth factor beta 1 and heterotypic cell interactions. J. Neuroimmunol. 1995, 58(1):101-110.
146. Lee K.B., Jeon J.H., Choi I., Kwon O.Y., Yu K., You K.H. Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Biochem. Biophys. Res. Commun. 2008, 366(4):905-909.
147. Tesseur I., Zou K., Esposito L., Bard F., Berber E., Can J.V., et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest. 2006, 116(11):3060-3069.
148. Das P., Golde T. Dysfunction of TGF-beta signaling in Alzheimer's disease. J. Clin. Invest. 2006, 116(11):2855-2857.